Quick Commercial Standouts Lacking Among 2016 US Launches
Executive Summary
The number of novel drugs approved by FDA in 2016 was down versus prior years, and many of the drugs that did launch are off to a slow start. The expectation is increasingly for drugs to build sales over time.
You may also be interested in...
A Year To Remember For US Drug Launches
A record-breaking 46 novel drugs and biologics were approved by FDA in 2017. The number of drugs that launched were plentiful and several were highly innovative, ushering in a new era of therapeutic breakthroughs. Turning pioneering medicines into commercial successes will be the test.
Is Amgen's FOURIER Enough For Physicians, Payers To Expand Repatha Use?
Detailed results presented at ACC show a reduction in risk of major adverse cardiovascular events, but perhaps not at the level hoped for by payers.
Sarepta Winning Payer War Over Duchenne Muscular Dystrophy Drug Coverage
Exondys 51 has been met with recommendations for restrictions by many insurers, but after consultations with experts and Sarepta execs coverage is expanding.